PORTRAZZA™ (necitumumab) approved as first-line therapy for metastatic, squamous non-small cell lung cancer, available at Biologics, Inc.
CARY, NC — November 30, 2015 — Biologics, Inc., is pleased to announce that it has been selected by Lilly Oncology […]